Darmstadt, Hesse, Germany
Executive Summary of Key Achievements 1. Establishment and fostering of substantial international scientific collaborations with key international academic and scientific institutes and societies, Advisory board member (FhG, LDC); 2. Development / implementation of innovative research and change management concepts and strategies for Novartis, Altana, Nycomed, Takeda, AbbVie and Merck KgaA; 3. Lead, coach and develop people; Professor at university since 1994; 4.Successfully leading and managing a R&D organisation with 5 multinational sites (Germany, Denmark, India, approx. 450 employees, annual budget responsibility for 80 Mio. €), translating two preclinical candidates per year into clinical phases; 5. Leading substantial change managements during R&D restructurings & mergers; 6. Author / Co-Author of 6 international patents; 7. Essential contributions to bring compounds to market (Pantoprazole, Elidel, Gleevec, Daxas), 30 years experience in pharmaceutical industry; 8. 99 Full Papers/Books/CD-ROMs, 73 Abstracts and 80 Teaching Lectures; Specialties: Networking & building relationships to academic research institutions, Change Management incl. leading organisations through reorganisations, Trouble shooting & problem solving in preclinical questions; Coaching, developing and mentoring young associates on scientific education, & leadership training programs incl. broad range of leadership skills, coaching & mentoring programs, scientific organisation of international congresses, supervision of PhD-students & lecturing at different universities
Executive Summary of Key Achievements: Successfully leading and managing a multinational R&D organisation, translating two preclinical candidates per year into clinical phases; Trouble shooting & problem solving in preclinical questions; Development / implementation of innovative research and change management concepts and strategies for Novartis, Altana, Nycomed, Takeda, AbbVie and Merck KgaA; Lead, coach and develop people; Professor at university since 1994; Successfully leading and managing a R&D organisation with 5 multinational sites (Germany, Denmark, India, approx. 450 employees, annual budget responsibility for 80 Mio. €), translating two preclinical candidates per year into clinical phases; Leading substantial change managements during R&D restructurings & mergers; Establishment and fostering of substantial international scientific collaborations with key international academic and scientific institutes and societies, Advisory board member (FhG, LDC); Author / Co-Author of 6 international patents; Essential contributions to bring compounds to market (Pantoprazole, Elidel, Gleevec, Daxas), 33 years experience in pharmaceutical industry; 99 Full Papers/Books/CD-ROMs, 73 Abstracts and 80 Teaching Lectures; Specialties: Networking & building relationships to academic research institutions, Change Management incl. leading organisations through reorganisations, Coaching, developing and mentoring young associates on scientific education, & leadership training programs incl. broad range of leadership skills, coaching & mentoring programs, scientific organisation of international congresses, supervision of PhD-students & lecturing at different universities
Teaching and lecturing of PhD students to open their mind set for career opportunities in the health care industry
Key Job Responsibilities: Translate very early innovation from preclinical discovery status into the GLP-conducting toxicology unit into a discovery and research oriented scientific value adding organisation; 35 FTEs, 12 Mio € Budget p.a. Key Achievements to date: Change and redirect the preclinical safety organisation from a regulatory GLP compliant toxicology towards a discovery and research oriented early safety unit. Providing substantial input into the early compound selection. Looking for solutions and mechanism based risk assessment combined with a strong customer and project orientation gives this new approach a central role in the profiling of new compounds. This newly formed AbbVie Center of Excellence for in vivo and analytical activities is delivering for medicines that will matter for the patients.
Bring very early science and groundbreaking innovation from academia and start ups into the value stream of a large pharmaceutical company. Create value through leveraging international connections within the academic cummunity. Looking for platform technologies, therapies or healthcare concepts which might change the current therapeutic area focus of Takeda or its business model.
Vice President heading the Discovery to Preclinical Development Organisation of total 480 employees in 4 sites in Constance, Mumbai, Roskilde & Willinghusen. 24 years successful in the field of discovery & develop.of drugs. Taking toxicological pathology as a basis, the main strength is integrated problem solving leading to substantial contributions to the regulatory process of many compounds (Pantoprazol, Gleevec, Elidel, Roflumilast, Ciclesonide, HDAC´s, VEGF-Inhibitors, Diovan, Venticute, FTY0720). A clinical and translational medicine team translating biomarker adn PK/PD modelling into proof of concept studies is part of this organisational structure. Participation in many safety assessment groups of new drug candidates. Implementation of support concepts for better & faster selection of new drug candidates. Author- & co-authorships in more than 100 publications &six international indication patents. Coaching, developing & mentoring young associates on scientific education, & leadership training programs. Scientific organisation of international congresses, supervision of PhD-students & lecturing at various universities. .
As head of the Institute for Preclinical Drug Safety of Nycomed GmbH, Prof. Germann was integrating his team of approx. 192 employees in Hamburg and Constance through the times of merging and substantial reorganisation into the new operating R&D model of Nycomed while keeping high performance standards.